Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-20. doi: 10.1200/EDBK_320085.
At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic leukemia, and multiple myeloma. CAR T cells for chronic lymphocytic leukemia, acute myeloid leukemia, and less common malignancies such as T-cell lymphomas and Hodgkin lymphoma are being tested in early-phase clinical trials worldwide. The purpose of this overview is to describe the current landscape of CAR T cells in hematologic malignancies, outline their outcomes and toxicities, and explain the outstanding questions that remain to be addressed.
在撰写本文时，已有五种抗 CD19 CAR T 细胞产品获得美国食品和药物管理局批准，用于治疗七种不同的淋巴恶性肿瘤适应症，包括 B 细胞非霍奇金淋巴瘤、儿童 B 细胞急性淋巴细胞白血病和多发性骨髓瘤。用于慢性淋巴细胞白血病、急性髓系白血病以及 T 细胞淋巴瘤和霍奇金淋巴瘤等罕见恶性肿瘤的 CAR T 细胞正在全球进行早期临床试验。本文的目的是描述 CAR T 细胞在血液恶性肿瘤中的现状，概述其疗效和毒性，并解释仍需解决的悬而未决的问题。
